


**Supplemental Table 1.** Cohort Characteristics

ID	Gender	Age Range	Completed COVID-19 Vaccinations at Enrollment	Days from End of N/R Therapy to Symptom Relapse	Days from End of N/R Therapy to Antigen Positivity	Days from End of N/R Therapy to Study Enrollment	Enrollment Viral Load (Log10 copies/mL)	Days from Diagnosis to Negative PCR	Positive Culture After Relapse (Y/N)	Days from Diagnosis to Negative Viral Culture
1	F	31-35	4	4	5	9	4.7	20	N	N/A
2	M	51-55	3	5	5	8	6.8	23	Y	16
3	F	46-50	3	7	4	7	4.2	23	N	N/A
4	F	51-55	5	4	4	7	6.1	18	N	N/A
5	F	46-50	4	2	5	6	7.3	16	Y	14
6	F	61-65	3	3	6	8	4.9	19	N	N/A
7	F	36-40	3	6	8	10	7.1	19	Y	19

N/R: nirmatrelvir-ritonavir

N/A: not applicable



**Supplemental Figure 1.** Amino acid sequence of NSP5 (main viral protease, or Mpro) for individuals with recurring infection following nirmatrelvir-ritonavir treatment, compared to reference WT genome (GenBank YP\_009725301.1). Ref-BA.2 (USA/MA-MGB-06410/2022) and Ref-BA.2.12.1 (USA/MA-MGB-05617/2022) genomes were collected via MGH surveillance sequencing and used as lineage-specific references. No mutations were found in drug-resistance conferring regions of the NSP5 gene of the six sequenced specimens.